about
Efficacy of the Quorum Sensing Inhibitor FS10 Alone and in Combination with Tigecycline in an Animal Model of Staphylococcal Infected WoundNXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA.Tigecycline challenge triggers sRNA production in Salmonella enterica serovar TyphimuriumSystematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcyclineGenetics of antimicrobial resistance in Staphylococcus aureus.Ceftaroline: A New Cephalosporin with Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)Development and validation of a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of tigecycline in rat brain tissues.Use of tigecycline in pediatric clinical practice.Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensionsAdjunctive Hyperbaric Oxygen Therapy or Alone Antibiotherapy? Methicillin Resistant Staphylococcus aureus Mediastinitis in a Rat Model.The efficacy of the quorum sensing inhibitor FS8 and tigecycline in preventing prosthesis biofilm in an animal model of staphylococcal infectionIn vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii.Synthesis and antibacterial activity of doxycycline neoglycosides.Emergence of blaKPC-containing Klebsiella pneumoniae in a long-term acute care hospital: a new challenge to our healthcare system.ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy.Vancomycin-induced neutropenia: is it dose- or duration-related?Efficacy and safety of tigecycline: a systematic review and meta-analysis.The epidemiology of the first described carbapenem-resistant Klebsiella pneumoniae outbreak in a tertiary care hospital in Saudi Arabia: how far do we go?Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective.Clinical relevance of the ESKAPE pathogens.Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.New antibacterial agents: patent applications published in 2010.Eravacycline for the treatment of intra-abdominal infections.Study on MICs of Tigecycline in Clinical Isolates of Carbapenem Resistant Enterobacteriaceae (CRE) at a Tertiary Care Centre in North India.Targeting the hard to reach: challenges and novel strategies in the treatment of intracellular bacterial infections.Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline.Tigecycline resistance in Acinetobacter baumannii mediated by frameshift mutation in plsC, encoding 1-acyl-sn-glycerol-3-phosphate acyltransferase.Target- and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic.Combined ramR mutation and presence of a Tn1721-associated tet(A) variant in a clinical isolate of Salmonella enterica serovar Hadar resistant to tigecycline.Decreased susceptibility to tigecycline in Acinetobacter baumannii mediated by a mutation in trm encoding SAM-dependent methyltransferase.Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.The Infinity War: How to Cope with Carbapenem-resistantManagement of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics
P2860
Q28552608-9C20EC77-23FA-481B-9161-20CC04E896D2Q30433276-FE1A3CF4-20D2-4545-849E-B25111C94537Q31089832-F7357605-A8C2-43E7-8B1B-5AA970CCCE3BQ33776590-7716A44E-1769-4A3B-BEB7-3F21F4A218BAQ34133346-61254432-4852-4D4F-92CB-9ED19342AA2CQ34389235-74958859-FB24-4169-B358-656E248798F4Q34984662-5B0ADA6B-6BBD-4961-8C54-7B05C5DF5FE4Q35117981-76F2B5DF-3329-45D7-91AB-01427997BE27Q35778366-0D2418E0-592F-493F-A650-1BF9C44E57A5Q36342430-54F59596-483E-49F5-BBA0-4F12CFFD3DBFQ36361921-BDFD24A8-826B-45D5-A3AA-C0173233CDB2Q36402879-CBB0437D-391F-4322-953D-B8984BC16CD8Q37139168-8E541F12-CB0E-482D-AE96-D516E0CBAE26Q37220041-D954D277-94D4-4C5B-AADA-191F3A941543Q37270510-421EA659-F7E3-4826-A447-CA5B52F56114Q37383945-4FE3F221-306C-4923-A371-2C82FBC0F0A3Q37392705-2F9499AD-2146-4366-8B3F-EAA475467A15Q37656243-4755CDF7-3C51-4E2F-AF81-1BC3D42F589CQ37869275-339769B5-2AD4-4FBB-98AC-5044303C3A41Q37891606-86F9E001-9D4C-4836-9033-40F21549F753Q37975111-0A2776B4-038E-46D8-890C-D21C1A643AD9Q38068604-7DB59185-1D27-4483-8B98-D1FB1B6DAB9FQ38086338-1975F4AA-FB56-400E-A16C-4ECF57BF7947Q38097120-0649040E-8DCA-4BDD-9BD9-452C741F569EQ38162949-6A52EB3B-12FD-4A62-83F5-8012A5B3F425Q38253877-9BCBEF5C-EE69-42CF-B096-C517888DA137Q38782367-A5562CE3-805B-4BB8-BDD7-D5D6989FCA8EQ39031276-A60E7746-DC04-4B6E-90B4-6756F592E8C9Q39683665-D7C5EF33-760E-4A21-9A00-FC7C230C7A5FQ40248088-3F7502B9-29EA-4C8B-B2FD-07C21591AC25Q40750517-3E92DFA5-E4A3-4AC8-808B-41A007F0E528Q41656779-DCAF6EF2-9D8F-4ED8-BF49-6C82046AB37DQ41879631-5864AEC7-96D1-4C6F-B0E2-FAC99D32D198Q42125230-C3FC17BB-557B-4D16-AE09-1C061E09CAEAQ42251871-1BAC65AC-2182-40C5-B0EE-BEA36BCD2EA0Q47662018-6E8314A8-D078-4189-8CDE-F7EBBB3EBCDEQ52695014-DDB660F1-20FE-4263-93D1-ED960BAE6BCEQ57118424-78D4CB3B-F37B-44BA-9C36-ECE7F540E554Q59135453-FC2A13CA-BA2D-4248-A502-700F0D63AAD0
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
A review of tigecycline--the first glycylcycline.
@ast
A review of tigecycline--the first glycylcycline.
@en
A review of tigecycline--the first glycylcycline.
@nl
type
label
A review of tigecycline--the first glycylcycline.
@ast
A review of tigecycline--the first glycylcycline.
@en
A review of tigecycline--the first glycylcycline.
@nl
prefLabel
A review of tigecycline--the first glycylcycline.
@ast
A review of tigecycline--the first glycylcycline.
@en
A review of tigecycline--the first glycylcycline.
@nl
P1476
A review of tigecycline--the first glycylcycline.
@en
P2093
Lance R Peterson
P304
P356
10.1016/S0924-8579(09)70005-6
P478
32 Suppl 4
P577
2008-12-01T00:00:00Z